Aptamer therapeutics useful in the treatment of complement-related disorders
Claude Benedict, Cambridge, MA (US); David Epstein, Huntington, NY (US); Charles Wilson, Concord, MA (US); Dilara McCauley, Cambridge, MA (US); Jeffrey Kurz, Winchester, MA (US); Markus Kurz, Basel (CH); Thomas Greene McCauley, Cambridge, MA (US); and James Rottman, Sudbury, MA (US)
Assigned to IVERIC bio, Inc., Parsippany, NJ (US)
Filed by IVERIC bio, Inc., Parsippany, NJ (US)
Filed on Mar. 12, 2021, as Appl. No. 17/200,536.
Application 13/525,680 is a division of application No. 11/884,411, granted, now 8,236,773, issued on Aug. 7, 2012, previously published as PCT/US2006/005215, filed on Feb. 14, 2006.
Application 17/200,536 is a continuation of application No. 16/289,374, filed on Feb. 28, 2019, granted, now 10,947,544.
Application 16/289,374 is a continuation of application No. 15/448,238, filed on Mar. 2, 2017, abandoned.
Application 15/448,238 is a continuation of application No. 14/573,423, filed on Dec. 17, 2014, granted, now 9,617,546, issued on Apr. 11, 2017.
Application 14/573,423 is a continuation of application No. 13/783,633, filed on Mar. 4, 2013, granted, now 8,946,184, issued on Feb. 3, 2015.
Application 13/783,633 is a continuation of application No. 13/525,680, filed on Jun. 18, 2012, granted, now 8,436,164, issued on May 7, 2013.
Application 11/884,411 is a continuation in part of application No. 11/058,134, filed on Feb. 14, 2005, granted, now 7,803,931, issued on Sep. 28, 2010.
Prior Publication US 2021/0332361 A1, Oct. 28, 2021
1. A compound or salt thereof, wherein the compound comprises the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCf UmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:4) and 1,3-bis(mPEG)-propyl-2-(4-butamide);
wherein fC and fU=2′-fluoro nucleotides, and mG and mA=2′-OMe nucleotides and all other nucleotides are 2′-OH and 3T indicates an inverted deoxy thymidine; and
wherein the compound binds specifically to complement system protein C5.